Interleukin-3 (IL-3): A Multifunctional Regulator of Hematopoiesis and Immunity

Interleukin-3 (IL-3), also known as Multi-Colony Stimulating Factor (Multi-CSF), is a key member of the hematopoietic growth factor family. Unlike IL-2, which primarily acts on mature lymphocytes, IL-3's core function lies in regulating the survival, proliferation, and differentiation of early hematopoietic stem/progenitor cells. It has a broad impact on the development of myeloid cells and the activity of various immune cells, playing a complex and vital role in maintaining basal hematopoiesis, emergency hematopoiesis, and allergic and inflammatory responses.

I. Overview of IL-3: Origin, Structure, and Receptor System

IL-3 is mainly produced by activated CD4⁺ T cells (particularly the Th2 subset), as well as by activated mast cells, basophils, natural killer T cells (NKT), and certain epithelial cells. It is a glycoprotein with a molecular weight of approximately 15-30 kDa, and its biological activity depends on binding to specific cell surface receptors.

The IL-3 receptor (IL-3R) belongs to the Type I cytokine receptor family, consisting of a specific α chain (CD123) and a β chain (CD131) shared with IL-5R and GM-CSFR. This receptor structure determines its unique and overlapping functions:

High-affinity receptor (αβ heterodimer): After IL-3 binds to the α chain, it recruits and dimerizes the β chain, forming a high-affinity signaling complex. The expression of CD123 is a key factor limiting the range of IL-3 target cells.

Signaling β chain (CD131): It has very low affinity for ligands on its own but, together with the α chain, is responsible for intracellular signal transduction. Due to its shared use with IL-5 and GM-CSF receptors, these cytokines exhibit partial functional overlap and competition.

Broad target cell range: IL-3R is expressed on multipotent hematopoietic stem cells, myeloid progenitor cells, basophils, mast cells, monocytes/macrophages, etc., forming the basis for its pleiotropic biological functions.

II. Core Mechanisms: Promoting Hematopoiesis and Regulating Immunity

The core role of IL-3 is as an early hematopoietic growth factor, while also profoundly influencing the function of various immune cells.

1. Promoting the Survival and Expansion of Hematopoietic Stem/Progenitor Cells

Supporting multilineage hematopoiesis: IL-3 can stimulate the proliferation and differentiation of the most primitive multipotent stem cells and committed progenitor cells (e.g., CFU-GEMM, CFU-GM, CFU-Meg, BFU-E), promoting the development of granulocytes, monocytes, megakaryocytes, erythrocytes, and even certain lymphocytes.

Anti-apoptotic effects: By activating survival signaling pathways (e.g., PI3K/Akt), IL-3 maintains the survival of progenitor cells under conditions lacking other growth factors, making it a key member of the "hematopoietic growth factor synergy" network.

2. Regulating Mast Cells and Basophils

Key factor for development and survival: IL-3 is an essential factor for the in vitro culture of mast cells and basophils and is crucial for their progenitor cell differentiation, survival, and tissue residency in vivo.

Enhancing effector functions: It enhances the survival of these cells and primes their functionality, enabling them to degranulate more intensely upon antigen stimulation (e.g., IgE cross-linking), releasing histamine, heparin, tryptase, and various inflammatory mediators, thereby driving Type I hypersensitivity and allergic disease progression.

3. Modulating Mature Myeloid Cell Functions

Enhancing phagocyte activity: IL-3 activates monocytes/macrophages and neutrophils, enhancing their chemotaxis, phagocytosis, and bactericidal capabilities while promoting the production of inflammatory cytokines (e.g., TNF-α, IL-1β).

Influencing dendritic cells: It participates in regulating the development and function of certain dendritic cell subsets, bridging innate and adaptive immunity.

III. Downstream Signaling Pathways: Executors of Cell Fate

Upon binding to its receptor, IL-3 primarily activates the following classical signaling pathways:

JAK-STAT pathway: Ligand binding induces receptor dimerization, activating the associated JAK2 kinase. JAK2 then phosphorylates tyrosine residues in the receptor's intracellular domain, providing docking sites for STAT5 (mainly STAT5A/B). Phosphorylated STAT5 forms dimers and translocates to the nucleus to regulate genes related to cell proliferation, differentiation, and survival (e.g., Bcl-2, Bcl-xL, c-Myc, Pim-1). This pathway is central to IL-3's pro-proliferative and anti-apoptotic effects.

PI3K-Akt pathway: The activated receptor complex recruits and activates PI3K, catalyzing the generation of PIP3, which then recruits Akt (PKB) to the cell membrane for phosphorylation and activation. Activated Akt promotes cell survival and metabolism by phosphorylating and inhibiting pro-apoptotic proteins (e.g., Bad, Caspase-9) and activating pathways such as mTOR.

Ras-MAPK pathway: Through adaptor proteins (e.g., Shc/Grb2/SOS), IL-3 activates Ras, initiating the Raf-MEK-ERK cascade. Phosphorylated ERK translocates to the nucleus, activating transcription factors such as c-Fos and c-Jun, primarily driving cell cycle progression and proliferation.

These pathways synergize and balance each other, collectively determining the cellular response to IL-3: proliferation, differentiation, or survival.

IV. IL-3 and Related Diseases

Abnormal expression or dysregulated signaling of IL-3 is closely associated with various pathological conditions.

1. Hematologic Malignancies

Acute myeloid leukemia (AML): Some AML cells aberrantly overexpress CD123 and rely on autocrine or paracrine IL-3 loops to promote malignant proliferation and survival. CD123 has become an important therapeutic target in AML.

Myelodysplastic syndromes (MDS): Abnormal levels of IL-3 and other growth factors in the bone marrow microenvironment may contribute to dysplastic hematopoiesis and disease progression.

Basophilic leukemia/mastocytosis: These diseases are closely linked to excessive activation of the IL-3 signaling pathway, making targeting IL-3R or its downstream signaling molecules a potential therapeutic strategy.

2. Allergic and Inflammatory Diseases

Asthma and allergic rhinitis: IL-3 is secreted by activated Th2 cells and mast cells, promoting the expansion and activation of basophils and mast cells, forming a positive feedback loop that exacerbates airway inflammation and hyperreactivity.

Atopic dermatitis: Elevated local IL-3 levels in the skin contribute to the recruitment and activation of mast cells and other inflammatory cells, leading to chronic itching and skin lesions.

3. Solid Tumors

Tumor microenvironment: IL-3 produced by tumor-infiltrating T cells or tumor-associated fibroblasts may indirectly influence tumor growth and metastasis by recruiting and modifying tumor-associated macrophages or promoting angiogenesis.

Potential therapeutic targets: CD123 expression has been detected on vascular endothelial cells or cancer stem cells in certain solid tumors (e.g., prostate cancer, glioblastoma), offering new avenues for targeted therapy.

4. Regenerative Medicine and Hematopoietic Support

Hematopoietic recovery: After myelosuppression (e.g., post-chemotherapy/radiotherapy) or bone marrow transplantation, exogenous IL-3 can be combined with G-CSF, GM-CSF, etc., to accelerate multilineage blood cell reconstitution.

In vitro expansion: IL-3 is used in the in vitro expansion culture of hematopoietic stem/progenitor cells, providing cell sources for cell therapy.

V. Future Perspectives: From Basic Research to Clinical Translation

In-depth research into IL-3 biology is driving its translation into clinical applications, primarily in the following directions:

CD123-targeted precision therapy: For CD123-overexpressing hematologic malignancies (especially AML), various targeted drugs have been developed:

Antibody-drug conjugates: Such as Tagraxofusp, which has made CD123-targeted therapy a reality.

Bispecific antibodies: Targeting both CD123 and T cell surface molecules (e.g., CD3) to recruit T cells for tumor killing.

CAR-T cell therapy: Developing CD123-targeted CAR-T cells for treating relapsed/refractory AML.

Novel strategies for allergic diseases: Developing IL-3 or receptor antagonists (e.g., blocking antibodies, small-molecule inhibitors) to disrupt the positive feedback loop of allergic inflammation, offering new treatments for severe asthma and other conditions.

Synergistic hematopoietic support: Further optimizing cytokine combinations including IL-3 for safer and more efficient clinical hematopoietic recovery or in vitro cell preparation.

Diagnostic and prognostic biomarkers: Measuring serum IL-3 levels or tumor cell CD123 expression may serve as auxiliary diagnostic, classification, or prognostic indicators for certain hematologic or allergic diseases.

Summary

As a key bridging molecule connecting the immune and hematopoietic systems, IL-3's functions extend far beyond stimulating cell proliferation. Through precise regulation of early hematopoiesis, specific shaping of basophil and mast cell lineages, and modulation of myeloid immune functions, it plays a central role in physiological hematopoiesis maintenance, emergency hematopoiesis mobilization, and pathological allergic/inflammatory responses. From its initial discovery as a "colony-stimulating factor" to today's status as a hot target for immunotherapy in hematologic malignancies, ongoing exploration of IL-3 continues to reveal its complex biological significance and holds promise for innovative therapies targeting malignant blood disorders and immune-related diseases. In the future, with deeper understanding of its roles in the tumor microenvironment and tissue homeostasis, IL-3-related research will continue to demonstrate its significant value in biomedicine.